Oxford BioDynamics PLC Grant of Canadian patent for EpiSwitch platform (0755V)

TIDMOBD

RNS Number : 0755V

Oxford BioDynamics PLC

19 July 2018

19 July 2018

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

Oxford BioDynamics announces grant of Canadian patent for its proprietary technology platform, EpiSwitch(TM)

Oxford BioDynamics Plc ("OBD" or the "Company"), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, today announces the grant of a key patent by the Canadian Intellectual Property Office covering EpiSwitch(TM), the Company's novel technology platform.

The Canadian patent, number 2642331, covers OBD's proprietary EpiSwitch(TM) technology designs for high resolution discovery and monitoring of regulatory conditional chromosome conformation signatures, as part of the regulatory architecture of the genome. As a biomarker modality, chromosome conformations have been shown to deliver highly informative stratifications of complex patient phenotypes, assist in better disease understanding and target identifications, and show high concordance with complex genetic and gene expression profiles. Predictive and prognostic stratifications developed by OBD on the basis of its proprietary EpiSwitch(TM) technology already offer significant improvements in patient stratifications, de-risking of drug discovery and development, and upgraded regulatory and market protection.

This patent will further extend coverage of OBD's proprietary technology platform, EpiSwitch(TM), in this important market. Counterparts to this patent have already been granted in the USA, Europe, China, Japan, Australia, India, Hong Kong, New Zealand, Singapore and South Africa.

Christian Hoyer Millar, Chief Executive Officer of Oxford BioDynamics, commented:

"We are pleased with the addition of this patent covering the use of our EpiSwitch(TM) technology in the Canadian market. This patent strengthens our global intellectual property position and further validates our novel approach to characterising structural modifications to genome architecture that have a profound effect on health."

-ENDS-

For further details please contact:

 
 Oxford BioDynamics Plc 
  Christian Hoyer Millar, 
  CEO 
  Paul Stockdale, CFO              [phone] 
 Shore Capital 
  Broker and Nominated Adviser 
  Stephane Auton 
  Edward Mansfield                [phone] 
 FTI Consulting 
  Financial Public Relations 
  Adviser 
  Brett Pollard 
  Natalie Garland-Collins         [phone] 
 

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.

The Company's award-winning, proprietary technology platform, EpiSwitch(TM), aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

In particular, EpiSwitch(TM) can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re--positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

UPDBSGDRSUBBGII

(END) Dow Jones Newswires

July 19, 2018 02:00 ET (06:00 GMT)